manilatimes9m
Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024
Operating profit increased by 25% in Danish kroner and by 26% at constant exchange rates (CER) to DKK 128.3 billion.
Novo Nordisk A/S Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - NVO
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...
Shareholder Rights Law Firm Robbins LLP Urges NVO Shareholders With Large Losses To Seek Counsel For The Novo Nordisk A/S Class Action
About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LL have been dedicated to helping shareholders recover losses, improve corporate governance ...
Shareholders With Losses In Novo Nordisk A/S Have Opportunity To Lead The Schall Law Firm In A Securities Fraud Case
LOS ANGELES, CA / ACCESS Newswire / February 4, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
MM&M14h
Lift tickets: 6 drug launches set for a hefty sales ramp
These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...
Will This New GLP-1 Drug be More Powerful Than Ozempic?
CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.
Centene's shares slip on higher Medicaid costs
Centene beat Wall Street estimates for fourth-quarter profit on Tuesday, helped by strength in its commercial health ...
Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
devdiscourse17h
Key Developments in Global Health: Merck, Pfizer, and Innovative Vaccines
This update provides insights into critical global health developments, including Merck's halt on Gardasil shipments to China ...
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss
Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...